Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | ACACB | O00763 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16891466 | 0.96 | L3MBTL1 (0.70) | L3MBTL1HRH3ACACBKMT2APOLB | |
| SCHEMBL11200681 | 0.91 | L3MBTL1 (0.76) | L3MBTL1HRH3ACACBKMT2ACYP1A2 | |
| SCHEMBL19717008 | 0.84 | L3MBTL1 (0.67) | L3MBTL1HRH3ACACBKMT2ACYP1A2 | |
| SCHEMBL10399987 | 0.84 | L3MBTL1 (0.67) | L3MBTL1HRH3ACACBKMT2ACYP1A2 | |
| SCHEMBL3140840 | 0.83 | KMT2A (0.53) | L3MBTL1HRH3KMT2APOLBTDP1 | |
| SCHEMBL5578262 | 0.82 | L3MBTL1 (0.65) | L3MBTL1HRH3ACACBKMT2APOLB | |
| SCHEMBL632892 | 0.82 | L3MBTL1 (0.65) | L3MBTL1HRH3ACACBKMT2ACYP1A2 | |
| SCHEMBL256037 | 0.82 | L3MBTL1 (0.65) | L3MBTL1HRH3ACACBKMT2ACYP1A2 | |
| SCHEMBL3903106 | 0.82 | L3MBTL1 (0.65) | L3MBTL1HRH3ACACBKMT2ACYP1A2 | |
| SCHEMBL13215733 | 0.82 | L3MBTL1 (0.65) | L3MBTL1HRH3ACACBKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010905-A | Pyrazolyl derivatives as anticancer agents | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4344702-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| EP-4663630-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | LG Chem, Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-20250375432-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2025-12-11 | — | — | US | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-12383540-B2 | Compounds that modulates AMPA receptor function | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2025-08-12 | — | — | US | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| EP-3386950-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-10-17 | — | — | EP | disclosed |
| CN-108368053-A | Substituted benzazepine derivatives as antibacterial compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-08-03 | — | — | CN | disclosed |
| WO-2017098440-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| CN-104507940-B | Heterocyclic compounds | 武田药品工业株式会社 | 2017-01-25 | — | — | CN | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
| CN-104507940-A | Heterocyclic compounds | TAKEDA PHARMACEUTICAL | 2015-04-08 | — | — | CN | disclosed |
| WO-2004046137-A1 | NEW TRICYCLIC ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375432-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | GRIN1, GRM1, GRIN2A | L3MBTL1 3079/4885HRH3 285/4885ACACB 1926/4885 |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | L3MBTL1 2322/4885HRH3 3535/4885ACACB 3794/4885 |
| US-12383540-B2 | Compounds that modulates AMPA receptor function | GRIN1, GRM1, GRIN2A | L3MBTL1 3006/4885HRH3 297/4885ACACB 2119/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | L3MBTL1 1667/4885HRH3 2417/4885ACACB 4377/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | L3MBTL1 4595/4885HRH3 2749/4885ACACB 506/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | L3MBTL1 2322/4885HRH3 3535/4885ACACB 3794/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | L3MBTL1 4116/4885HRH3 776/4885ACACB 3349/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | L3MBTL1 1667/4885HRH3 2417/4885ACACB 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.